Lung

, Volume 187, Issue 3, pp 149–152 | Cite as

Stabilization of Lung Function and Clinical Symptoms in a Patient with Cystic Fibrosis (CF) After Institution of Infliximab: A Monoclonal Antibody that Binds Tumor Necrosis Factor alpha

Article

Abstract

The most characteristic feature of airway inflammation in cystic fibrosis (CF) is the persistent infiltration of massive numbers of neutrophils. Although inflammation is primarily a protective response to injury, it has the potential to cause considerable harm when it is excessive. Recent recognition of the prominent role of inflammation has prompted the investigation of treatments designed to control inflammation in the CF lung. We report a 35-year-old man with abrupt stabilization of his rapidly progressive CF and forced expiratory volume (FEV1) after starting infliximab for his rheumatoid arthritis. This effect was sustained for 8 years while continuing to use twice-monthly infliximab.

Keywords

Tumor necrosis alpha Infliximab Inflammation Bronchiectasis Stabilization Forced expiratory volume 

References

  1. 1.
    Gibson RL, Burns JL, Ramsey BW (2003) Pathophysiology and management of pulmonary infections in cystic fibrosis. Am J Respir Crit Care Med 168(8):918–951. doi: 10.1164/rccm.200304-505SO PubMedCrossRefGoogle Scholar
  2. 2.
    Brown RK, Kelly FJ (1994) Role of free radicals in the pathogenesis of cystic fibrosis. Thorax 49(8):738–742. doi: 10.1136/thx.49.8.738 PubMedCrossRefGoogle Scholar
  3. 3.
    Barnes PJ, Karin M (1997) Nuclear factor-kappaB: a pivotal transcription factor in chronic inflammatory diseases. N Engl J Med 336(15):1066–1071. doi: 10.1056/NEJM199704103361506 PubMedCrossRefGoogle Scholar
  4. 4.
    Bonfield TL, Panuska JR, Konstan MW et al (1995) Inflammatory cytokines in cystic fibrosis lungs. Am J Respir Crit Care Med 152(6 Pt 1):2111–2118PubMedGoogle Scholar
  5. 5.
    Belaaouaj A, McCarthy R, Baumann M, Gao Z, Ley TJ, Abraham SN et al (1998) Mice lacking neutrophil elastase reveal impaired host defense against gram negative bacterial sepsis. Nat Med 4(5):615–618. doi: 10.1038/nm0598-615 PubMedCrossRefGoogle Scholar
  6. 6.
    Antoniu SA (2006) Etanercept for refractory asthma therapy. Expert Opin Investig Drugs 15(10):1279–1281. doi: 10.1517/13543784.15.10.1279 PubMedCrossRefGoogle Scholar
  7. 7.
    Feldmann M, Brennan FM, Foxwell BM, Taylor PC, Williams RO, Maini RN (2005) Anti-TNF therapy: where have we got to in 2005? J Autoimmun 25:26–28. doi: 10.1016/j.jaut.2005.09.006 SupplPubMedCrossRefGoogle Scholar
  8. 8.
    Tracey KJ, Fong Y, Hesse DG et al (1987) Anti-cachectin/TNF monoclonal antibodies prevent septic shock during lethal bacteraemia. Nature 330(6149):662–664. doi: 10.1038/330662a0 PubMedCrossRefGoogle Scholar
  9. 9.
    Guilbault C, Saeed Z, Downey GP, Radzioch D (2007) Cystic fibrosis mouse models. Am J Respir Cell Mol Biol 36(1):1–7. doi: 10.1165/rcmb.2006-0184TR PubMedCrossRefGoogle Scholar
  10. 10.
    Auerbach HS, Williams M, Kirkpatrick JA, Colten HR (1985) Alternate-day prednisone reduces morbidity and improves pulmonary function in cystic fibrosis. Lancet 2(8457):686–688. doi: 10.1016/S0140-6736(85)92929-0 PubMedCrossRefGoogle Scholar
  11. 11.
    Eigen H, Rosenstein BJ, FitzSimmons S, Schidlow DV (1995) A multicenter study of alternate-day prednisone therapy in patients with cystic fibrosis Cystic Fibrosis Foundation Prednisone Trial Group. J Pediatr 126(4):515–523. doi: 10.1016/S0022-3476(95)70343-8 PubMedCrossRefGoogle Scholar
  12. 12.
    Konstan MW, Byard PJ, Hoppel CL, Davis PB (1995) Effect of high-dose ibuprofen in patients with cystic fibrosis. N Engl J Med 332(13):848–854. doi: 10.1056/NEJM199503303321303 PubMedCrossRefGoogle Scholar
  13. 13.
    Konstan MW, Schluchter MD, Xue W, Davis PB (2007) Clinical use of Ibuprofen is associated with slower FEV1 decline in children with cystic fibrosis. Am J Respir Crit Care Med 176(11):1084–1089. doi: 10.1164/rccm.200702-181OC PubMedCrossRefGoogle Scholar
  14. 14.
    Chmiel J, Konstan MW (2007) Inflammation and anti-Inflammatory therapies for cystic fibrosis. Clin Chest Med 28(2):331–346. doi: 10.1016/j.ccm.2007.02.002 PubMedCrossRefGoogle Scholar
  15. 15.
    Yarden J, Radojkovic D, De Boeck K et al (2005) Association of tumour necrosis factor alpha variants with the CF pulmonary phenotype. Thorax 60(4):320–325. doi: 10.1136/thx.2004.025262 PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2009

Authors and Affiliations

  1. 1.Division of Pulmonary/Critical Care and Sleep MedicineMemorial Hospital of Rhode IslandPawtucketUSA
  2. 2.Cystic Fibrosis CenterProvidenceUSA

Personalised recommendations